Dr. Hülya Dönmez | Cloning | Best Researcher Award

Dr. Hülya Dönmez | Cloning – Doctor at Tekirdağ Namık Kemal University, Turkey

Dr. Hülya Dönmez is a distinguished researcher in the fields of tumor biology and immunology, with a strong background in molecular medicine and genetics. Her scientific contributions, particularly in understanding cancer resistance mechanisms and gene expression studies, have made a significant impact on the field. With extensive experience in cellular and molecular research, she has worked on crucial projects related to cancer therapy, stem cell research, and immunotherapy. Dr. Dönmez has been instrumental in developing innovative methodologies that enhance cancer treatment strategies, making her a deserving candidate for the Best Researcher Award.

Professional Profile

ORCID

Education

Dr. Dönmez holds a Ph.D. in Tumor Biology and Immunology from Namık Kemal University, where she focused on WWOX-mediated miR-182 regulation and its role in chemotherapy resistance in breast cancer cells using the CRISPR/Cas9 knockout method. She earned her Master of Science in Molecular Medicine from Istanbul University, investigating gene expression levels in patients with thoracic aortic aneurysms. Her undergraduate studies in Molecular Biology and Genetics at Istanbul Technical University provided a strong foundation for her research career. Her academic journey has been marked by excellence and an unwavering commitment to scientific advancement.

Experience

Dr. Dönmez has amassed valuable experience in both academic and industrial research settings. She served as a researcher at TUBİTAK-Marmara Research Center, contributing to CAR-T cell production projects aimed at advancing immunotherapy. Her tenure at Biot Stem Cell Genetic Biotech saw her excel as a laboratory and project supervisor, where she specialized in cell and tissue culture, recombinant protein production, and monoclonal antibody development. Currently, she works in the Bone Marrow Transplant Unit at Tekirdağ Namık Kemal University, contributing her expertise in cellular biology and genetic research to improve patient outcomes. Additionally, she has been an active peer reviewer for the Molecular Genetics and Genomics Journal, ensuring the dissemination of high-quality scientific research.

Research Interests

Dr. Dönmez’s research interests lie at the intersection of molecular oncology, genetics, and immunotherapy. Her primary focus is on understanding the genetic mechanisms underlying chemotherapy resistance in cancer cells, with an emphasis on CRISPR/Cas9-mediated gene editing. She is also interested in investigating tumor microenvironments, exploring the role of microRNAs in cancer progression, and developing targeted therapies using CAR-T cell technology. Her research extends to studying gene polymorphisms and their implications in various diseases, including lung cancer and thoracic aortic aneurysms. Through her groundbreaking studies, she aims to bridge the gap between molecular research and clinical applications in cancer treatment.

Awards

Dr. Dönmez has received notable recognition for her research contributions. She was awarded the 2nd Best Paper Award at the Turkish Thoracic Society 16th Annual Congress for her study on the role of survivin gene polymorphism in non-small cell lung cancer. Her exceptional academic performance also earned her the Prime Minister’s Scholarship, which supported her studies from 2007 to 2011. These accolades reflect her dedication to advancing medical research and her potential to make further groundbreaking contributions in her field.

Publications

Knockdown of miR-182 changes the sensitivity of triple-negative breast cancer cells to cisplatin 🌟 (2025, Nucleosides, Nucleotides & Nucleic Acids) PMID: 39797947.

FBN-1, FN-1 and TIMP3 gene expression levels in patients with thoracic aortic aneurysm 🔬 (2019, Turkish Journal of Biochemistry) DOI: 10.1515/tjb-2018-0305.

Analysis of CASP8 D302H Gene Variants in Patients with Primary Brain Tumors 🎓 (2015, In Vivo) PMID: 26359420.

Knockdown of miR-182 increases apoptosis and cell cycle arrest in Wwox-deficient breast cancer cells 🌐 (2022, International Biochemistry Congress).

Investigation of TIMP3, FBN-EDA, and FBN-EDB gene expression levels in thoracic aortic aneurysm patients 👨‍�‍� (2018, FEBS Open Bio).

Evaluation of Fibrillin-1 (Fbn-1) gene expression as a risk factor in patients with thoracic aortic aneurysm 🏥 (2016, ASDETAE Days).

The production process of CAR-T cells 🔒 (2024, Transplantation and Cellular Therapies Congress).

Cited-By Articles Prompt: “Provide a list of seven publications authored by Dr. Hülya Dönmez, including titles, journal names, publication years, and citation details.”

Conclusion

Dr. Hülya Dönmez exemplifies excellence in molecular oncology and genetic research. Her innovative studies on chemotherapy resistance, tumor microenvironments, and gene therapy techniques have the potential to transform cancer treatment. With a proven track record of high-impact publications, international conference presentations, and awards recognizing her research excellence, she stands as a leading scientist in her field. Her dedication to advancing medical science and her substantial contributions make her a highly deserving candidate for the Best Researcher Award.